Biological therapies in the systemic management of psoriasis: International Consensus Conference
- 19 July 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 151 (s69), 3-17
- https://doi.org/10.1111/j.1365-2133.2004.06070.x
Abstract
Psoriasis is a chronic, immune‐mediated disorder that usually requires long‐term treatment for control. Approximately 25% of patients have moderate to severe disease and require phototherapy, systemic therapy or both. Despite the availability of numerous therapeutic options, the long‐term management of psoriasis can be complicated by treatment‐related limitations. With advances in molecular research and technology, several biological therapies are in various stages of development and approval for psoriasis. Biological therapies are designed to modulate key steps in the pathogenesis of psoriasis. Collectively, biologicals have been evaluated in thousands of patients with psoriasis and have demonstrated significant benefit with favourable safety and tolerability profiles. The limitations of current psoriasis therapies, the value of biological therapies for psoriasis, and guidance regarding the incorporation of biological therapies into clinical practice are discussed.Keywords
This publication has 82 references indexed in Scilit:
- Long-term efalizumab therapy safely maintains psoriasis area and severity index improvement: preliminary results from an open-label trialJournal of the American Academy of Dermatology, 2004
- Safety of multiple courses of alefacept in combination with other psoriasis therapies: a study that reflects the clinical practice settingJournal of the American Academy of Dermatology, 2004
- Long-term use of intravenous alefacept: safety and off-treatment responses in patients who have received four or more courses of therapyJournal of the American Academy of Dermatology, 2004
- The quality of life of patients with severe psoriasis treated with infliximabJournal of the American Academy of Dermatology, 2004
- CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized studyJournal of the American Academy of Dermatology, 2003
- Current systemic therapies for psoriasis: where are we now?Journal of the American Academy of Dermatology, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- An approach to the treatment of moderate to severe psoriasis with rotational therapyJournal of the American Academy of Dermatology, 1993
- Fumaric acid therapy in psoriasis: Results and side effects of 2 years of treatmentJournal of the American Academy of Dermatology, 1992
- Combined methotrexate-ultraviolet B therapy in the treatment of psoriasisJournal of the American Academy of Dermatology, 1982